Your browser doesn't support javascript.
loading
Xanthine oxidase inhibitors in ischaemic heart disease
Zdrenghea, M; Sitar-Tǎut, A; Cismaru, G; Pop, D.
Affiliation
  • Zdrenghea, M; s.af
  • Sitar-Tǎut, A; s.af
  • Cismaru, G; s.af
  • Pop, D; s.af
Article in En | AIM | ID: biblio-1260359
Responsible library: CG1.1
ABSTRACT
Increased uric acid levels are correlated with cardiovascular disease, particularly with ischaemic heart disease. Xanthine oxidase inhibitors, especially allopurinol, lower the risk of ischaemic heart disease due to their effects on reactive oxygen species and endothelial function. In chronic stable angina pectoris, allopurinol increases the median time to ST depression, time to chest pain, and total exercise time. On the other hand, it has been reported that allopurinol has a beneficial effect on ischaemic patients referred for angioplasty, but there are insufficient data regarding its effect on acute myocardial infarction patients. Moreover, other important actions of allopurinol are regression of left ventricular hypertrophy and improvement in the results of cardiac rehabilitation. The efficacy of allopurinol has recently been acknowledged by the European Society of Cardiology guidelines for stable angina pectoris, but the particular role of allopurinol in ischaemic heart disease patients is not fully established.
Subject(s)
Search on Google
Database: AIM Main subject: South Africa / Xanthine Oxidase / Allopurinol / Myocardial Ischemia Country/Region as subject: Africa Language: En Journal: Cardiovasc. j. Afr. (Online) Year: 2017 Document type: Article
Search on Google
Database: AIM Main subject: South Africa / Xanthine Oxidase / Allopurinol / Myocardial Ischemia Country/Region as subject: Africa Language: En Journal: Cardiovasc. j. Afr. (Online) Year: 2017 Document type: Article
...